| 262.42 Data as of May 22 |  +2.46 / +0.95%Today’s Change | 107.31 Today|||52-Week Range 283.99 | +53.40% Year-to-Date |
| Sanofi/REGN's Dupilumab Data Published - Analyst Blog May 22 / Zacks.com | Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) May 20 / TheStreet.com |
| This Is Incredibly Bullish Behavior May 22 / TheStreet.com | Sanofi/REGN Commence Enrollment - Analyst Blog May 15 / Zacks.com |
| 5 Stocks Underperforming Today In The Drugs Industry May 20 / TheStreet.com |
| Previous close | 259.96 |
| Today’s open | 260.06 |
| Day’s range | 257.08 - 274.50 |
| Volume | 1,058,455 |
| Average volume (3 months) | 1,106,897 |
| Market cap | $25.5B |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -41.06% |
| Earnings growth (next 5 years) | +34.36% |
| Revenue growth (last year) | +209.20% |
| P/E ratio | 34.9 |
| Price/Sales | 11.75 |
| Price/Book | 20.31 |
| Today’s change | Today’s % change | |
|---|---|---|
| CBSTCubist Pharmaceutica... | +0.65 | +1.17% |
| ARIAARIAD Pharmaceutical... | +0.90 | +5.13% |
| PRXLPAREXEL Internationa... | -0.69 | -1.49% |
| ISISIsis Pharmaceuticals... | -0.42 | -2.02% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $1.4B |
| Annual profit (last year) | $750.3M |
| Net profit margin | 54.43% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Leonard S. Schleifer, MD, PhD |
Chief Financial Officer & Senior VP-Administration Murray A. Goldberg, MBA |
Corporate headquarters Tarrytown, New York |
.
